Spironolactone for High Blood Pressure After Pregnancy

This study is looking at whether a medication called spironolactone can help women who had high blood pressure during pregnancy (preeclampsia or gestational hypertension) to lower their blood pressure after delivery. You might be able to join if you are at least 18 years old, had high blood pressure during pregnancy, and had a BMI of 25 or higher before or early in your pregnancy. Participants will receive either 25 mg of spironolactone or a placebo (an inactive pill) once a day for 12 weeks after delivery. The main goal is to see if spironolactone helps reduce your average blood pressure measured over 24 hours at 36 weeks after delivery. The study is currently unclear on its recruitment status and plans to enroll 204 women.

Study design
This is an interventional study comparing spironolactone to a placebo. It plans to enroll 204 participants.
What's involved
Participants will take a study medication daily for 12 weeks. Blood pressure will be measured at 36 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 36 weeks after delivery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07041281

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

Recruiting
PHASE2Ages 18+InterventionalTreatment
Massachusetts General Hospital
~204 participants
Updated 2026-04-03 on ClinicalTrials.gov
What's tested:spironolactone 25 mg orally once dailyPlacebo tablet to match spironolactone

At a glance

Recruiting sites
2 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean 24-hour ambulatory diastolic blood pressure
Measured over 36 weeks
Preeclampsia
Gestational Hypertension
3 sites across 2 states
Massachusetts2
Pennsylvania1

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Females aged ≥18 years
HDP (gestational hypertension or preeclampsia) without pre-pregnancy chronic hypertension
BMI ≥25 kg/m2 prior to pregnancy or in the first trimester
Requirement for antihypertensive medication within one week of delivery
Ability to provide informed consent

Exclusion

LV ejection fraction \<50% or history of clinical heart failure with reduced or preserved ejection fraction
Hypertrophic or other genetic cardiomyopathy
Hyperkalemia: potassium \>5.3 mEq/L
BMI at screening ≥50 kg/m2
Pre-pregnancy diabetes
Estimated glomerular filtration rate (eGFR) \<60mL/min/1.73 m2
Cirrhosis
Primary aldosteronism
Intention to become pregnant within 9 months
Active substance abuse
Other serious medical illnesses or concerns about protocol adherence/ mortality within 9 months
Participation in another interventional clinical study
Hypersensitivity to spironolactone
Addison's disease
Concomitant use of eplerenone or finerenone
  • Mean 24-hour ambulatory diastolic blood pressure36 weeks

    24-hour BP monitoring will be performed as part of end-of-study assessments using a validated ambulatory BP monitor.